Form 8-K aTYR PHARMA INC For: Mar 14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
aTyr Pharma (LIFE) PT Lowered to $16 at RBC Capital
March 15, 2024 6:39 AM EDTRBC Capital analyst Kennan MacKay lowered the price target on aTyr Pharma (NASDAQ: LIFE) to $16.00 (from $19.00) while maintaining a Outperform rating.
The analyst comments "From LIFEs YE call, Early Access Program demand underscores the enthusiasm across sites as the ph.III EFZO-FIT... More
